- Home
- OKYO vs CCIF Comparison
OKYO vs CCIF Comparison
Compare OKYO & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OKYO | CCIF |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.3M | 84.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | OKYO | CCIF |
|---|---|---|
| Price | $1.72 | $3.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.33 | N/A |
| AVG Volume (30 Days) | ★ 361.7K | 238.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 25.90% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $3.21 |
| 52 Week High | $3.35 | $7.90 |
Technical Indicators
Market Signals| Indicator | OKYO | CCIF |
|---|---|---|
| Relative Strength Index (RSI) | 43.36 | 31.45 |
| Support Level | $1.52 | N/A |
| Resistance Level | $2.25 | $5.87 |
| Average True Range (ATR) | 0.13 | 0.19 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 57.58 | 14.55 |
Price Performance
Historical ComparisonAbout OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.